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SUMMARY Porphyrias are an uncommon, heterogeneous group 
of metabolic diseases caused by inherited or acquired deficiency 
of specific enzymes in the heme biosynthetic pathway resulting in 
an excess of porphyrins (red-brown pigments) and their precursors. 
Accumulation of heme precursors, such as porphyrinogens that are 
spontaneously oxidized to porphyrins, is responsible for various 
clinical features. Porphyrias are classified into three groups: 
erythropoietic, hepatic and hepatoerythropoietic, depending on the 
primary organ affected. Porphyria cutanea tarda (PCT) is the most 
common porphyria, characterized by defective uroporphyrinogen III 
decarboxylase enzyme. There are three types of PCT with typical 
skin manifestations. Patients with PCT present with skin fragility, 
erosions, vesicles, bullae, and milia in sun-exposed areas of the skin, 
sometimes periorbital mottled hyperpigmentation and hypertrichosis, 
sclerodermoid changes and ulceration. We present the most common 
pathogenetic, clinical, diagnostic, and therapeutic features of PCT 
and other types of porphyria.
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INTRODUCTION  
 Porphyrias are a heterogeneous group of met-
abolic diseases caused by inherited or acquired 
deficiency of specific enzymes in the heme bio-
synthetic pathway resulting in an excess of por-
phyrins and their precursors (porphyrin is a red-
brown pigment) (1). Porphyrias are classified into 
three groups: erythropoietic, hepatic and hepato-
erythropoietic, depending on the primary organ af-
fected (Table 1) (1,2). 
 The accumulation of heme precursors in por-
phyrias, including porphyrinogens that are spon-
taneously oxidized to their respective porphyrins, 
is responsible for various clinical features (1). 
Two main types of clinical manifestation include 
life-threatening attacks of acute porphyria and 
chronic skin photosensitization (3). Acute porphyr-
ias include acute intermittent porphyria, variegate 
porphyria, hereditary coproporphyria, and δ-ami-
nolevulinic acid (ALA) dehydratase deficiency, 
while chronic porphyrias include porphyria cu-
tanea tarda (PCT), erythropoietic porphyria and 
erythropoietic protoporphyria (3).
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BIOSYNThETIC pAThWAY Of hEME
 Heme is synthesized in all nucleated cells, but 
the majority is formed in hepatocytes and erythro-
blasts in bone marrow. Heme is necessary for the 
transport and metabolism of oxygen (4). The bio-
synthetic pathway of heme starts in mitochondria 
when the amino acid glycine (which is found in all 
cells) and succinyl coenzyme A (derived from Krebs 
cycle) are condensed to form ALA (Fig. 1) (5). This 
reaction is catalyzed by 5-ALA synthase and is the 
rate limiting step in the biosynthetic pathway of 
heme. The activity of the 5-ALA synthase enzyme 
can be inhibited by heme, glucose and hematin. 
The next stage of the pathway occurs in the cy-
tosol when two molecules of ALA are condensed 
to form porphobilinogen, a molecule containing a 
monopyrrole ring. The reaction is catalyzed by 5-
ALA dehydratase. Then four porphobilinogen mol-
ecules are combined to form a linear tetrapyrrole, 
hydroxymethylbilane by hydroxymethybilane syn-
thase, and then the pathway splits (5). The uro-
porphyrinogen-III cosynthetase enzyme cyclizes 
linear hydroxymethylbilane to uroporphyrinogen 
III, while in the absence of the enzyme uroporphy-
rinogen I is formed. Uroporphyrinogen III is then 
converted by uroporphyrinogen III decarboxylase 
(UROD) to its respective coproporphyrinogen III, 
while uroporphyrinogen I is spontaneously con-
verted to coproporphyrinogen I. Only coproporphy-
rinogen III participates further in heme synthesis, 
being oxidized by coproporphyrinogen oxidase to 
protoporphyrinogen IX, which is returned to the 
mitochondria. It is then oxidized by protoporphy-
rinogen oxidase to protoporphyrin IX. At the end 
of heme synthesis iron is added by ferrochelatase 
to protoporphyrin IX to make heme (5). Different 
forms of porphyrias are caused by enzyme defi-
ciencies, starting from 5-ALA synthase and ending 
with ferrochelatase, which are almost all inherited 
in an autosomal dominant pattern (2,5). Low clini-
cal penetrance of all the autosomal dominant por-
phyrias is an important feature (4). The enzyme 
deficiencies are permanent, but clinical symptoms 
of porphyrias are intermittent and usually do not 
present until after puberty, especially in PCT (the 
most common porphyria), acute intermittent por-
phyria and variegate porphyria (5).
 For the disorder to become clinically manifest, 
an additional decrease in enzyme activity is re-
quired, which may result from direct, organ spe-
cific inhibition of the enzyme, e.g., hepatocellular 
carcinoma, or from a mutation in the genes that 
affects transcription and/or translation of enzymes 
of heme synthesis. These effects may be caused 
by mutation in the genes other than those directly 
involved in heme synthesis, e.g., mutation in the 
hemochromatosis gene. Clinical manifestation is 
triggered by medications, hormones (particularly 
progesterone), fasting and medical illness. 
 Induction of ALA synthetase increases hepatic 
heme synthesis and enzyme deficiencies become 
apparent as heme precursors accumulate. If heme 
breakdown is increasing, the negative feedback 
loop causes direct induction of ALA synthetase 
and clinical manifestations of porphyrias become 
apparent (5). Heme is the prosthetic group of pro-
teins such as hemoglobin, myoglobin, catalase, 
peroxidase and cytochrome P 450. Cytochrome 
P 450 is heme oxygenase (about 40% of the he-
patic heme is incorporated into enzyme), which 
metabolizes a significant number of commonly 
used drugs. Medications cause direct induction of 
this enzyme, increasing its production, then lead 
to heme reduction (heme is incorporated into cy-
tochrome P 450) and the negative feedback loop 
causes induction of ALA synthetase. The enzymes 
involving heme synthesis are defective and heme 
precursors accumulate. Toxins including alco-
hol, metals (iron), hexachlorobenzene and many 
other chemical substances are metabolized in the 
liver by cytochrome P 450 and can cause clini-
cal manifestation of the most common cutaneous 
porphyria, PCT. Also, hepatitis C virus (especially 
in HIV-positive patients) can cause a mutation in 
the genes that affects directly transcription and/
or translation of the enzymes of heme synthesis 
(5,6).
 Porphobilinogens are oxidized to uroporphy-
rinogens, coproporphyrins and protoporphyrins, 
and their solubility changes as they are metabo-
lized (5). Therefore, ALA, porphobilinogen and 
uroporphyrinogen are hydrophilic and excreted in 
the urine, while coproporphyrin and protoporphy-
rin are lipophilic and are found in the stool.
 Porphyrins (except for ALA and porphobilino-
gen) absorb the lower range of visible light in the 
Soret band (400-410 nm), and after exposure to 
visible light they show red fluorescence. This ab-
sorbed light energy is then transferred to cellular 
structures of hepatocytes and erythroblasts, and 
molecular oxygen is transformed into singlet oxy-
gen. Free radicals and singlet oxygen peroxide 
phospholipids of the lysosomal biomembranes. 
Potent degrading lysosomal enzymes, includ-
ing proteases, lipases and glycosidases lead to 
tissue damage. After heme precursors in eryth-
rocytes have absorbed enough energy, photohe-
molysis occurs. Peripheral erythrocytes are no 
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longer responsive to blood loss and hypoxia. An 
elevated reticulocyte count indicates an increased 
erythrocyte production compensating for the on-
going loss of erythrocytes (photohemolysis). 
 The most phototoxic porphyrin is protoporphy-
rin, which produces free radicals and singlet oxy-
gen that damage a variety of cellular structures. 
Photoprotection from both UVA and the lower 
range of visible light is necessary in porphyria pa-
tients due to the peak activation of heme precur-
sors in the Soret band (5). 
ClASSIfICATION AND TYpES Of 
pORphYRIA
 Traditionally, porphyrias have been divided 
into erythropoietic and hepatic, while accord-
ing to some authors porphyrias are classified as 
erythropoietic, hepatic, and hepatoerythropoietic 
(Table 1) (1,5). Only one porphyria is purely eryth-
ropoietic, i.e. congenital erythropoietic porphyria, 
which is an autosomal recessive variant, suggest-
ing that all reticulocytes have to miss the neces-
sary enzyme in order to manifest the disease. In 
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figure 1. Biosynthesis of heme, with sites of enzyme deficiencies in porphyria; adapted from: Braun-Falco 
O, Plewig G, Wolff HH, Burgdorf WHC, eds. The porphyrias. In: Braun-Falco O, Plewig G, Wolff HH, Burg-
dorf WHC, eds. Dermatology. 2nd completely revised edition. Berlin: Springer-Verlag; 2000. pp.1309-26.
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erythropoietic protoporphyria, both red blood cells 
and hepatocytes have enzyme deficiencies, while 
in other porphyrias the main problem is in hepato-
cytes (7-10). 
 Porphyrias have been classified by clinicians 
as acute and chronic. Acute porphyrias include 
acute intermittent porphyria, variegate porphyria, 
hereditary coproporphyria, and ALA dehydratase 
deficiency, while chronic porphyrias include PCT, 
erythropoietic porphyria and erythropoietic proto-
porphyria (3,11-13). Acute porphyrias are caused 
by deficiency of the hepatic heme synthesis en-
zymes, with the possible emergency admission for 
sudden attacks of abdominal pain, or may cause 
neuropsychiatric symptoms (2,5).
 There is also secondary porphyria caused 
by acute lead poisoning. Lead blocks the action 
of the ALA dehydratase enzyme and massive 
amounts of ALA accumulate in the urine, where 
they serve as markers of lead intoxication, leading 
to symptoms of acute intermittent porphyria. Lead 
also causes increased fragility and decreased red 
blood cell survival due to direct effect on the red 
cell membrane. Patients with chronic renal failure 
on dialysis sometimes develop clinical manifes-
tations that are indistinguishable from the cuta-
neous lesions seen in PCT, and are associated 
with increased carboxylated porphyrins, mainly 
uroporphyrins, that accumulate in serum. Identify-
ing these uncommon porphyrins requires a highly 
specialized laboratory (5).
 All types of porphyria show excess of porphy-
rin metabolites in the blood, urine or feces, and 
in various tissues such as skin and liver. Certain 
porphyrin metabolites (porphyrinogens) accumu-
late in the skin and are auto-oxidized to become 
porphyrins. Porphyrins absorb UVA light in Soret 
band range, and these excited porphyrins gener-
ate peroxides that cause blisters seen in PCT and 
variegate porphyria (3).
 Acute intermittent porphyria (AIP) is caused by 
deficiency of the hydroxymethylbilane synthase 
enzyme that combines four porphobilinogen mol-
ecules to form linear tetrapyrrole (Table 1). This 
type of porphyria is characterized by increased 
concentrations of 5-ALA and PBG in plasma 
and urine (2). Hereditary coproporphyria is acute 
porphyria due to the defect in the conversion of 
coproporphyrinogen III to protoporphyrinogen III 
(2). Variegate porphyria is acute porphyria char-
acterized by clinical manifestations that are indis-
tinguishable from the cutaneous lesions seen in 
AIP. PCT and other porphyrias present clinically 
as skin sensitivity to light (photosensitivity), with 
possible disfiguration and scarring (2). 
 The skin lesions in PCT, variegate porphyria, 
hereditary coproporphyria, and congenital erythro-
poietic porphyria manifest with mechanical fragil-
ity, subepidermal bullae, hypertrichosis, and pig-
mentation (3). Protoporphyrin is the predominant 
porphyrin in patients with erythropoietic protopor-
phyria. Protoporphyrin and Soret band radiation 
cause the release of mast cell mediators causing 
erythema and edema without skin lesions seen in 
other types of porphyria.  
 Laboratory diagnosis of porphyrias includes 
measurements of both relevant enzymes and 
metabolites in plasma, urine, feces and erythro-
cytes. The most important test for the diagnosis 
of acute porphyrias is the measurement of PBG 
in urine and plasma (2). Then ALA accumulates 
in the urine, where it serves as a marker of lead 
intoxication.
 It is also important to analyze urine (ALA, por-
phobilinogen and total urine porphyrins, mea-
sured by ion-exchange resins, chromatographic 
photometric techniques, high-pressure liquid chro-
matography) and erythrocytes (erythrocyte fluo-
rescence determine erythropoietic protoporphyria 
and congenital erythropoietic porphyria), or to 
measure porphobilinogen deaminase (high-pres-
sure liquid chromatography is needed to separate 
various porphyrin products in the urine) and feces 
(high-pressure liquid chromatography)(5). 
pORphYRIA CUTANEA TARDA 
 Porphyria cutanea tarda (PCT) (Günther 1922; 
Waldenström 1937; Ippen 1959) is the most com-
mon porphyria, characterized by defective uro-
porphyrinogen III decarboxylase (UROD) enzyme 
and includes three types of PCT with typical skin 
manifestations (1,5). Patients present with skin 
fragility, erosions, vesicles, bullae, and milia in 
sun-exposed areas of the skin, sometimes perior-
bital mottled hyperpigmentation and hypertricho-
sis, sclerodermoid changes and ulceration (Fig. 
2). It is characterized by increased uroporphyrins 
such as 8-,7-, 6-, 5-, and 4-carboxyl porphyrins in 
urine and isocoproporphyrin in stool (1,14-16).
 There are three types of PCT: two types of he-
reditary PCT (types II and III) and acquired PCT 
(type I). Acquired PCT (PCT type I) is the most 
common type of PCT (80% of patients with PCT) 
with negative family history. The disease is caused 
by mutation in the genes for the hepatic enzyme 
UROD, where the hepatic enzyme activity is 
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reduced by 50%, although the structural protein 
is present. In extrahepatic locations, the enzyme 
structure and function are normal (17-19).
 Family history is positive in hereditary PCT 
types II and III, and they are inherited in an au-
tosomal dominant pattern. Hereditary PCT type II 
is caused by a mutation in the genes that affects 
directly transcription and/or translation of the he-
patic and erythrocyte enzyme UROD, while hered-
itary PCT type III is caused by mutation only in the 
genes of the hepatic enzyme UROD; the enzyme 
level is reduced to about 50% of normal in all tis-
sues (1,5). 
 In the majority of patients, a mutation in the 
UROD gene is not enough to cause clinical mani-
festations of PCT (4). However, in contrast to the 
autosomal dominant acute porphyrias (with the 
same enzyme activities, and symptoms present or 
not); in familial PCT the hepatic enzyme activity 
is decreased to below half-normal in symptomatic 
individuals. 
 The additional decrease in hepatic UROD ac-
tivity results from reversible inactivation by an 
iron-dependent process, probably initiated by a 
number of possible triggers such as alcohol, hep-
atotropic viruses, iron intake, oral estrogens and 
genetic factors that may influence susceptibility to 
these causes (4).
 There is a strong genetic association of co-inher-
itance of UROD and hemochromatosis (HFE) gene 
mutations, resulting in the earlier onset of symp-
toms. Other candidate predisposing genes include 
ALAS 1 and cytochrome P 450 (4,10,11). However, 
there is similar hepatic iron content in PCT patients 
with and without HFE mutations, and clearly involv-
ing other factors related to iron metabolism.
 It should also be noted that PCT patients have 
an increased risk of clinical relapse and hepato-
cellular carcinoma, particularly those with long-
standing untreated disease, and should be kept 
under surveillance.
 Although precise data on the epidemiology 
of PCT are lacking (more than a single enzyme 
defect is involved), it was observed that in aver-
age dermatological practice, PCT accounts for 
80%-90% of porphyria patients with an incidence 
of 1:25 000 (5). The male/female ratio has been 
reported to be 1:1 in both inherited types of PCT, 
but in the acquired form men are by far more fre-
quently affected.
 Etiopathogenesis of pCT 
 Defective UROD activity results in the charac-
teristic porphyrin profile of PCT. In familial PCT, 
there are several genomic DNA mutations result-
ing in defective UROD (indicating that it is a ge-
netically heterogeneous entity) (1). 
 The porphyrins absorb Soret band radiation, 
generating reactive oxygen species. Free radicals 
and singlet oxygen peroxide the phospholipids of 
the lysosomal biomembranes. Potent degrading 
lysosomal enzymes, including proteases, lipases 
and glycosidases, lead to tissue damage and re-
lease of inflammatory mediators, neutrophils, and 
the activation of the complement system. The lack 
of direct effect of uroporphyrins (the predominant 
porphyrin in patients with PCT) on mast cells ex-
plain the manifestations of PCT, without erythema 
and edema. It has also been shown that uropor-
phyrins stimulate collagen synthesis by fibroblasts 
in vitro, which may explain the sclerodermoid skin 
lesions occurring both in sun-exposed and sun-
protected areas of the skin in porphyria patients 
(1,11). 
 The hereditary types of PCT tend to have a 
somewhat earlier onset in the first decades of life, 
while acquired cases of PCT typically appear after 
the age of 30.
 In hereditary and acquired forms of PCT, about 
20% of patients, the family history of PCT is posi-
tive. It has been confirmed that both forms were 
trigerred by alcohol abuse (60%), estrogens 
(25%) and liver disease (20%) (1). Association of 
PCT with human immunodeficiency virus (HIV) 
infection and hepatitis C infection was confirmed 
(1,14). 
 Medications and hepatomas are responsible 
for chronic reaction in 5% of patients with PCT, 
while in about 10% of patients, the cause is un-
known (5). Medications cause direct induction of 
figure 2. Classic clinical presentation of a patient 
with porphyria cutanea tarda.
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the cytochrome P 450 enzyme in hepatocytes. 
Cytochrome P 450 is heme oxygenase (about 
40% of the hepatic heme is incorporated into the 
enzyme), which metabolizes a significant number 
of commonly used drugs. Thus, the medications 
in the hepatic porphyria lists can be employed for 
routine use in PCT patients, but it is wise to avoid 
any potentially hepatotoxic medications in PCT pa-
tients. High-dose chloroquine and hydroxychloro-
quine therapy causes acute reactions, but severe 
reactions are rare. Besides medications, there are 
other triggering agents in PCT: alcohol (the ma-
jor risk factor, acts at many levels of heme syn-
thesis); estrogens (oral contraceptives, replace-
ment estrogens and estrogens given to males 
with prostate cancer); iron (elevated hepatic iron 
stores, often to twice normal), hexachlorobenzene 
(e.g., PCT-like illness with chronic PCT changes, 
arthritis, neurologic problems and elevated fecal 
and urine porphyrins in a region of southeastern 
Turkey where wheat seeds treated with hexachlo-
robenzene were used for food), and dioxin (5,8).
Clinical features of pCT
 Genetic predisposition and exposure to se-
lected exogenous agents contribute to the cutane-
ous manifestations of PCT (1). The disorder can 
start at any age in the autosomally dominant in-
herited form (types II and III), while the acquired 
form (type I) usually begins in adulthood. Several 
exogenous agents such as alcohol, estrogen, iron 
overload and polychlorinated aromatic hydrocar-
bons precipitate the onset of PCT by contributing 
to excessive hepatic porphyrinogenesis. The most 
common clinical presentation of PCT is skin fragil-
ity, manifested as erosions, vesicles or bullae in 
sun-exposed areas, usually on the dorsa of hands 
and forearms (Fig. 2). Another typical aspect is in-
creased skin fragility, and thus the slightest trauma 
will damage the sun-exposed skin and the wound 
healing is delayed. Bullae and erosions heal with 
hyper- and hypopigmented atrophic scars and mil-
ia. Other cutaneous changes include facial hyper-
trichosis along the temples and cheeks, periorbital 
mottled hyperpigmentation, sclerodermoid lesions 
on both sun-exposed and sun-protected areas of 
the neck, face and chest, scarring alopecia; dys-
trophic calcification with ulceration, and rarely 
onycholysis (1,5). 
 There often are no sensations of discomfort fol-
lowing sun exposure (such as burning and sting-
ing), and no gastrointestinal and neuropsychiatric 
symptoms.
 Bullous lesions in PCT appear as noninflammed 
subepidermal blisters in sun-exposed skin, com-
monly on the back of the hand, cheeks or temples, 
ranging in size from a few millimeters to several 
centimeters, and are quite stable and painless 
(5,15). The blisters rupture and may produce atro-
phic scars, hypo- and hyperpigmentation and mil-
ia, producing a polymorphous clinical picture, but 
patients almost never associate blisters with acute 
sunlight exposure and often deny photosensitivity  
(Fig. 2).
 Other reversible lesions include hypertrichosis 
as a common feature, often involving the tem-
ples, connecting the eyebrows to the hairline and 
cheeks. Facial hyperpigmentation resembling me-
lasma, and heliotrope discoloration are also mani-
festations of PCT (5,15).
 PCT patients often show chronic actinic dam-
age, with possible Favre-Racouchot disease, 
diffuse actinic elastosis, deep furrows and wrin-
kles. The presence of marked actinic damage in 
a young patient should suggest the possibility of 
PCT (Birda sign) (5,15).
 Sclerodermoid lesions (pseudoscleroderma) 
are also seen in porphyria patients, mostly on the 
skin of the lateral aspects of the face and neck, as 
firm and indurated skin, with small erosions, hem-
orrhagic areas, crusts or varioliform scars (5).
 A number of patients have been reported with 
both PCT and lupus erythematosus, which is clini-
cally important, as high-dose chloroquine therapy 
used in lupus erythematosus can cause acute re-
actions in PCT patients (5).
Laboratory findings in PCT 
 Plasma porphyrin determination is a good 
screening test for all types of porphyria with cu-
taneous manifestations. Diagnosis should only 
be made after evaluation of the complete por-
phyrin profile in plasma, erythrocytes, urine, and 
feces (1).
 Porphyrin profiles are essential in differenti-
ating PCT from two other less common types of 
porphyria, namely variegate porphyria and heredi-
tary coproporphyria (which can be clinically indis-
tinguishable from PCT) (Table 1) (1). In variegate 
porphyria, the predominant porphyrin is copro-
porphyrin, while ALA and porphobilinogen are in-
creased in urine during attacks (1). 
 Porphyrins can be identified by serum analy-
sis, which is of particular importance in renal di-
alysis patients, but urine analysis is crucial. The 
most appropriate test is 24-h urine evaluation; 
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screening tests on spot urines are unreliable (5). 
There is a massive increase in all urine porphy-
rins but coproporphyrins usually predominate. The 
urine may be discolored. Feces analysis is not 
mandatory but also shows elevated levels of por-
phyrins and the presence of isocoproporphyrins is 
taken as diagnostic.
 There are several quantitative and qualitative 
measurement tests of porphyrins, including fluo-
rescence under Wood’s light (invisible long-wave 
ultraviolet radiation at 360 nm), which is a non-
specific finding but serves as a screening test in 
PCT.  If the level of porphyrins is too low, false-
negative result can be obtained. The 24-hour 
urine test is a quantitative measurement of por-
phyrins. If porphyrins are present, the urine may 
be amber-red or burgundy. In most forms of por-
phyria, increased levels of porphyrins are found in 
the urine. The urine in PCT shows elevated level 
of uroporphyrins (isomers I>III) and 7-carboxyl 
porphyrin (isomers III>I), and lesser elevations of 
6-, 5-, and 4-carboxyl porphyrins. Urine tests are 
not as accurate as fluorescent spectrophotometric 
analysis of plasma. A sharp emission peak at 619 
nm confirms PCT. The test can also be done on 
a fresh stool specimen. In PCT the predominant 
stool porphyrin precursor is isomer III of isocop-
roporphyrin, with lesser amounts of uroporphyrin, 
coproporphyrin, and 7-carboxyl porphyrin (1,15). 
The analysis of erythrocytes for determination of 
UROD levels is used to separate the acquired 
form (normal levels) from the familial form (50% 
reduction). 
 Other laboratory tests that should be performed 
include complete blood count (to assess hemoglo-
bin and hematocrit levels prior to therapy), serum 
iron, ferritin and total iron binding capacity (to as-
sess iron stores, which are increased in more than 
30% of patients), liver enzymes and hepatitis virus 
(including hepatitis C) screen and ANA screening 
(1,14). In patients who have risk factors for HIV 
infection, HIV serology should be considered. 
 Biopsy of a vesicle shows a characteristic sub-
epidermal blister, with intact dermal papillae ris-
ing irregularly from the floor of the bullae into the 
cavity and only sparse inflammatory cells in the 
dermis. Thickened capillary walls in the superfi-
cial dermis are best observed in sections stained 
with periodic acid Schiff (PAS) stain and represent 
multiple layering of basal lamina, as detected by 
electron microscopy (1). Biopsy of a vesicle, which 
should include the edge of the lesion, is indicated 
to differentiate PCT from other blistering diseases. 
It is important to think about possible histological 
features of associated lupus erythematosus. The 
clinical picture of sclerodermoid lesions may ap-
pear as scleroderma, while histological features 
such as separation at the epidermal-dermal junc-
tion and amorphous perivascular material suggest 
PCT. In addition, there is usually actinic elastosis 
or other elastic fiber changes, while in scleroder-
ma the elastic fibers are normal.
 The differential diagnosis of PCT includes drug-
induced pseudoporphyria, caused by medications 
such as furosemide, nonsteroid anti-inflammatory 
drugs; nalidixic acid and tetracycline, clinically in-
distinguishable from PCT, but porphyrin studies 
are negative. Bullous lesions in patients with renal 
dialysis may be caused by the increased serum 
porphyrin. Epidermolysis bullosa acquisita may 
look like PCT and can be diagnosed by the pres-
ence of antibodies to type VII collagen. Excessive 
use of tanning beds cause blisters and increased 
skin fragility independent of burning (5).
 Direct immunofluorescence shows deposition 
of immunoglobulins and C3 at the basement mem-
brane zone and in the walls of blood vessels in the 
superficial dermis (1). Indirect immunofluorescent 
examination is negative.
 The prognosis of PCT is good if the patient does 
not have permanent liver damage and avoids fu-
ture hepatic insults. A small percentage of patients 
either have a hepatoma or may develop one. 
Some clinicians consider PCT a paraneoplastic 
marker and close monitoring is required (5).
Therapy of pCT
 It is important that complete elimination of al-
cohol, estrogen, iron, and environmental toxins 
results in clinical clearing of reversible skin lesions 
of PCT in 2 months to 2 years (1). Protection from 
both ultraviolet and visible light is required, and 
use of physical sun-blockers such as micronized 
titanium dioxide is recommended, while chemical 
sunscreens do not effectively absorb the Soret 
band.
 Phlebotomy is the treatment of choice; 250-500 
mL of blood should be removed weekly or biweek-
ly until hemoglobin drops to 10 to 11 g/dL or until 
serum iron drops to 50 to 60 µg/dL), but clinical 
improvement is not noticeable until 3 to 6 months 
and the time necessary for remission ranges from 
months to years (7,20,21).
 Oral antimalarial agents are quite effective and 
some physicians use them as first-line therapy. For 
example, chloroquine phosphate base, 125 mg 
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twice weekly for 8-18 months in very low dosages 
may be given. Thereat, chloroquine forms a water-
soluble complex with porphyrins and uroporphyrins 
are rapidly eliminated by the urine. It also causes 
a minor hepatotoxic reaction with the release of 
porphyrins, which are excreted in the urine. They 
can also be useful in patients who are anemic, in 
HIV positive patients or in those that cannot tol-
erate phlebotomy for other reasons. Chloroquine 
is usually used in very low dosages, as at higher 
dosages severe hepatotoxic response may oc-
cur (5). During this therapy, liver function must be 
monitored carefully, especially at the beginning of 
therapy. Ocular toxicity is possible but unlikely at 
such low dosages. Some clinicians prefer to com-
bine chloroquine 125 mg twice weekly with more 
modest phlebotomies, usually 250 mL every other 
week. It is important to measure plasma uropor-
phyrin in order to monitor the progression of PCT. 
Therapy should be continued until plasma uropor-
phyrin drops below 10 mmol/L. 
 Other less commonly used treatments include 
cholestyramine, iron chelators, high-dose hydroxy-
chloroquine, and erythropoietin (1,20,22). 
 The iron load is nowhere near as high as in he-
mochromatosis, so usually there is no use for the 
aggressive regimens described for this disease (5). 
The hemoglobin or hematocrit levels should not be 
driven below 12 g/dL or 36%, respectively. Serum 
iron and urine porphyrin levels drop slowly as the 
clinical findings improve. Blistering and skin fra-
gility improve first, often after several months, hy-
pertrichosis and sclerodermoid changes may get 
better over years, while atrophic scars and white 
milia are permanent skin lesions. 
 Other approaches include the use of iron-bind-
ing chelating agents, both orally and intravenous-
ly, and combining erythropoietin with phlebotomy 
in anemic patients. Local therapy in porphyria 
patients is usually not needed, except for routine 
wound care for eroded blisters. Sunscreens may 
reduce the chronic actinic changes but seem to 
help little against blistering (5).
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